Repligen Co. (NASDAQ:RGEN) Director Acquires $37,672.50 in Stock

Repligen Co. (NASDAQ:RGEN) Director Margaret Pax bought 250 shares of the company’s stock in a transaction on Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Repligen Stock Down 3.8 %

Repligen stock opened at $139.34 on Friday. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $200.23. The stock has a market cap of $7.81 billion, a price-to-earnings ratio of -273.22, a PEG ratio of 4.54 and a beta of 0.95. The company’s 50-day moving average price is $156.47 and its two-hundred day moving average price is $148.40. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Institutional Trading of Repligen

A number of hedge funds and other institutional investors have recently modified their holdings of RGEN. Champlain Investment Partners LLC grew its holdings in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after acquiring an additional 850,345 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Repligen by 11.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Repligen by 183.1% during the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after purchasing an additional 594,189 shares in the last quarter. Groupama Asset Managment grew its stake in shares of Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock worth $58,142,000 after purchasing an additional 400,680 shares during the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Repligen in the 4th quarter worth approximately $53,428,000. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on RGEN shares. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Evercore ISI assumed coverage on Repligen in a report on Tuesday. They set an “in-line” rating and a $155.00 target price for the company. TD Cowen assumed coverage on Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Finally, Canaccord Genuity Group increased their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.